Waldenström's macroglobulinemia differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}}{{AE}}{{MGS}} | |||
{{Waldenström's macroglobulinemia}} | {{Waldenström's macroglobulinemia}} | ||
Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including: | Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including: | ||
*Chronic lymphocytic leukemia/small lymphocytic lymphoma: | *[[Chronic lymphocytic leukemia]]/[[small lymphocytic lymphoma]]: | ||
::*Always express CD5, usually CD23 positive<ref name="UTD">Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015</ref> | ::*Always express CD5, usually CD23 positive<ref name="UTD">Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015</ref> | ||
*B-cell prolymphocytic leukemia: | *[[B-cell prolymphocytic leukemia]]: | ||
::*Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)<ref name="UTD"></ref> | ::*Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)<ref name="UTD"></ref> | ||
*Follicular lymphoma: | *[[Follicular lymphoma]]: | ||
::*Express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA<ref name="UTD"></ref> | ::*Express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA<ref name="UTD"></ref> | ||
::*Bone marrow infiltration of small, cleaved cells that are usually paratrabecular<ref name="pubM">{{cite journal |vauthors=Sahin I, Leblebjian H, Treon SP, Ghobrial IM |title=Waldenström macroglobulinemia: from biology to treatment |journal=Expert Rev Hematol |volume=7 |issue=1 |pages=157–68 |year=2014 |pmid=24405328 |doi=10.1586/17474086.2014.871494 |url=}}</ref> | ::*Bone marrow infiltration of small, cleaved cells that are usually paratrabecular<ref name="pubM">{{cite journal |vauthors=Sahin I, Leblebjian H, Treon SP, Ghobrial IM |title=Waldenström macroglobulinemia: from biology to treatment |journal=Expert Rev Hematol |volume=7 |issue=1 |pages=157–68 |year=2014 |pmid=24405328 |doi=10.1586/17474086.2014.871494 |url=}}</ref> | ||
::*Rearrangement of Bcl-2 | ::*Rearrangement of Bcl-2 | ||
*Multiple myeloma: | *[[Multiple myeloma]]: | ||
::*Express CD138, CD38, CD79a, and VS38c and CD56(70%)<ref name="UTD"></ref> | ::*Express CD138, CD38, CD79a, and VS38c and CD56(70%)<ref name="UTD"></ref> | ||
::*Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and renal insufficiency<ref name="pubM"></ref> | ::*Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and [[renal insufficiency]]<ref name="pubM"></ref> | ||
::*Translocation involving chromosome 11 (t 11;14) | ::*Translocation involving chromosome 11 (t 11;14) | ||
*Mantle cell lymphoma: | *[[Mantle cell lymphoma]]: | ||
::* Express CD5+ and CD23-, surface IgM and IgD and cyclin D1 in majority of cases<ref name="UTD"></ref> | ::* Express CD5+ and CD23-, surface IgM and IgD and cyclin D1 in majority of cases<ref name="UTD"></ref> | ||
::*Infiltration of bone marrow by monomorphous, small lymphoid cells with irregular nuclei<ref name="pubM"></ref> | ::*Infiltration of bone marrow by monomorphous, small lymphoid cells with irregular nuclei<ref name="pubM"></ref> | ||
| Line 28: | Line 29: | ||
::*Infiltrates the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern<ref name="pubM"></ref> | ::*Infiltrates the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern<ref name="pubM"></ref> | ||
::*Most common cytogenetic abnormalities are loss of 7q (19%) along with +3q (19%) and +5q (10% ) | ::*Most common cytogenetic abnormalities are loss of 7q (19%) along with +3q (19%) and +5q (10% ) | ||
=References== | =References== | ||
Revision as of 20:01, 12 November 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia differential diagnosis |
|
FDA on Waldenström's macroglobulinemia differential diagnosis |
|
CDC on Waldenström's macroglobulinemia differential diagnosis |
|
Waldenström's macroglobulinemia differential diagnosis in the news |
|
Blogs on Waldenström's macroglobulinemia differential diagnosis |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia differential diagnosis |
Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:
- Always express CD5, usually CD23 positive[1]
- Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)[1]
- Express CD138, CD38, CD79a, and VS38c and CD56(70%)[1]
- Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and renal insufficiency[2]
- Translocation involving chromosome 11 (t 11;14)
- Marginal zone lymphoma:
References=
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015
- ↑ 2.0 2.1 2.2 2.3 Sahin I, Leblebjian H, Treon SP, Ghobrial IM (2014). "Waldenström macroglobulinemia: from biology to treatment". Expert Rev Hematol. 7 (1): 157–68. doi:10.1586/17474086.2014.871494. PMID 24405328.